Total Funding
88
61
Total FundingPost-IPO Equity raised
Growth Score
-9 pts
Heat Score
1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
42062
Prelude Therapeutics designs and develops small molecule therapies targeting key drivers of cancer cell growth and resistance.
- Krishna Vaddi: Chief Executive Officer and FounderPast Role: Orsenix, Chief Executive Officer
- Peggy Scherle: Chief Scientific Officer
About the Company
Prelude Therapeutics is a developer of novel therapies intended to target key drivers of cancer cell growth, survival, and resistance. The company's offerings include developing a pipeline of novel, orally bioavailable, small-molecule therapies to target critical intervention points in pathways of resistance to overcome treatment failure in
cancer, enabling healthcare providers to discover potential treatments that offer hope to people with cancer.
Prelude Therapeutics was founded in 2016 by Krishna Vaddi and is based in Wilmington, Delaware.
